Misonix

Canaccord Genuity acts as Sole Bookrunning Manager for US$34.6 million public offering of common stock by Misonix, Inc.

Canaccord Genuity is pleased to announce that on January 27, 2020, it completed a public offering of common stock for Misonix, Inc. (NASDAQ: MSON) (the “Company”). The Company issued a total of 1,868,750 shares of its common stock at a price to the public of $18.50 per share, which includes the full exercise of the underwriters’ overallotment option. The gross proceeds to the Company, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately $34.6 million. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include investment in sales and marketing initiatives and funding growth opportunities such as collaborations and acquisitions of complementary products or technologies.

Canaccord Genuity acted as Sole Bookrunning Manager for the offering.

Misonix, Inc. designs, manufactures and markets various minimally invasive surgical ultrasonic medical devices and markets and distributes TheraSkin, a clinically proven, minimally manipulated, split-thickness skin allograft that is cryopreserved to retain living cells and growth factors while maintaining a mature native human dermal architecture. Misonix’s ultrasonic devices are used for precise bone sculpting, removal of soft and hard tumors, wound debridement and ultrasonic aspiration, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care and maxillo-facial surgery. The Company’s TheraSkin product is used in advanced wound care and is designed to help healthcare professionals treat difficult-to-heal and chronic wounds.

Canaccord Genuity is focused on the corporate finance needs associated with growth companies in the United States, Canada, Europe and Asia. We are structured to provide our clients with a full range of global investment banking services, including corporate finance, research, sales and trading. Our thematic research focusing on companies around the world provides our firm with unique access to growth investors. In the last twelve months, the firm executed 185 public financings that raised approximately $32.8 billion and advised on 83 M&A assignments.

The Canaccord Genuity team included Matt Steere, Jeff Barlow, Jennifer Pardi, Brian O’Connor, Tara Hartigan, Mike Wright, Tyler Munson, Oliver Park and Brooke Szczygiel.